Gecko Biomedical’s first product may be a surgical sealant, but it has eyes on much more. The sealant's polymer has many potential applications.

Illumina Ventures reeled in $130 million in new funding, bringing its genomics-ventured fund to $230 million.

The lawsuit alleges that Patrick Miles schemed for more than a year to badmouth NuVasive and build a stake in Alphatec.

Shockwave's new financing will expand commercialization of its ultrasound balloon treatment for calcified artery disease and boost R&D.

The series B equips Recursion to move beyond its initial focus on repurposing by applying its technology to the discovery of novel targets and drugs.

Analytics 4 Life bagged $25 million to support a clinical trial of its device that noninvasively screens for coronary artery disease.

BioSensics picked up more than $2.5 million in an NIH grant to develop a remote monitoring device for Huntington disease.

Days after the FDA approved Optinose’s nasal polyp drug, its commercialization will be the focus of a post-IPO spending spree.